Immune system disorders

Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK

Retrieved on: 
Friday, July 30, 2021

We are excited to further demonstrate the potential of 1104 to change disease management and treatment experience for the diversity of patients living with allergic diseases.

Key Points: 
  • We are excited to further demonstrate the potential of 1104 to change disease management and treatment experience for the diversity of patients living with allergic diseases.
  • Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies.
  • 1104 is a peptide derived from a natural immune-regulatory protein and is entering Phase 2 clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease.
  • The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

Annual Congress 2021 of the European Academy of Allergy and Clinical Immunology

Retrieved on: 
Sunday, July 11, 2021

Avapritinib is a potent and selective inhibitor of KIT D816V, the underlying cause of approximately 95 percent of all SM cases.

Key Points: 
  • Avapritinib is a potent and selective inhibitor of KIT D816V, the underlying cause of approximately 95 percent of all SM cases.
  • The data are being presented today, 11 July 2021, in a late-breaking oral presentation at theEuropean Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress2021.
  • By targeting the primary genetic driver of SM, avapritinib has significant potential to advance treatment for patients with this life-threatening disease."
  • [1]
    The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956.

USA Equities Corp. Acquires AllergiEnd®Assets

Retrieved on: 
Thursday, June 24, 2021

These properties are a great strategic fit that further support our recurring revenue business model focused on non-specialist medical practitioners, which is a large and growing addressable market.

Key Points: 
  • These properties are a great strategic fit that further support our recurring revenue business model focused on non-specialist medical practitioners, which is a large and growing addressable market.
  • We are very well positioned in this market given our deep applications expertise and industry relationships, said Troy Grogan, CEO of USA Equities Corp.
    AllergiEnds FDA-cleared diagnostic equipment and products allow primary care providers to diagnose and treat many common chronic allergies in their offices.
  • The Companys products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases.
  • In particular, the Companys statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements.

Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

Retrieved on: 
Wednesday, June 23, 2021

The unique aspect of 1104 is that it works upstream in the biological pathway that drives inflammation in allergic diseases like EoE.

Key Points: 
  • The unique aspect of 1104 is that it works upstream in the biological pathway that drives inflammation in allergic diseases like EoE.
  • Revolo Bio plans to advance 1104 through two Phase 2 trials: one in patients with eosinophilic esophagitis and one in patients with allergen sensitivity, while exploring its potential for other allergic diseases.
  • 1104 is a peptide derived from a natural immune-regulatory protein and is entering phase 2 clinical trials for patients with eosinophilic esophagitis (EoE) and allergic disease.
  • The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

Equillium to Present at the JMP Securities Life Sciences Conference

Retrieved on: 
Wednesday, June 9, 2021

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.

Key Points: 
  • LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.
  • Bruce Steel, Equilliums chief executive officer, will provide a high-level overview of itolizumabs mechanism of action and review each of the ongoing clinical programs, with a focus on topline data from the companys EQUATE study in acute graft-versus-host disease, to be presented at EHA on Friday, June 11, 2021.
  • Mr. Steel and other members of Equilliums leadership team will be available for one-on-one meetings during the conference.

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

Retrieved on: 
Monday, June 7, 2021

Craig Paterson, M.D., Allakos Senior Vice President of Clinical Development and Medical Affairs, will be promoted to CMO.

Key Points: 
  • Craig Paterson, M.D., Allakos Senior Vice President of Clinical Development and Medical Affairs, will be promoted to CMO.
  • We thank Henrik for his many contributions to the lirentelimab development program, said Robert Alexander, Ph.D., chief executive officer of Allakos.
  • Dr. Paterson joined Allakos as SVP of clinical development and medical affairs in March 2021, reporting to Dr. Rasmussen.
  • The Companys lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE).

Ready, Set, Food Announces $3.5 Million Raised In Most Recent Funding Round, Fueled By New Investment From Edward-Elmhurst Health

Retrieved on: 
Thursday, June 3, 2021

Developed by parents, for parents, following first-hand experiences with their kids' own childhood food allergies, the all-star team behind Ready, Set, Food!

Key Points: 
  • Developed by parents, for parents, following first-hand experiences with their kids' own childhood food allergies, the all-star team behind Ready, Set, Food!
  • With one in every twelve babies developing a food allergy each year, the investors' steadfast support ensures that Ready, Set, Food!
  • "I am proud to once again increase my investment from Shark Tank in Ready, Set, Food!
  • Founded by parents for parents, with a team of all-star physicians and leaders in allergy research, Ready, Set, Food!

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

Retrieved on: 
Tuesday, June 1, 2021

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application.
  • SER-155 represents a novel microbiome technology with the potential to address antibiotic-resistant bacterial bloodstream infections and further to modulate host immunomodulatory responses to decrease graft-versus-host disease.
  • Additionally, the engraftment of SER-155 bacteria (a measure of pharmacokinetics) and the efficacy of SER-155 in preventing infections and GvHD will be evaluated.
  • This milestone represents another exciting opportunity to support patients through Seres microbiome therapeutic candidates and illustrates the potential for microbiome therapeutics to change how disease is treated for immunocompromised patients, said Eric Shaff, Chief Executive Officer at Seres.

IGM Biosciences to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021

MOUNTAIN VIEW, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 1:00 p.m. EDT.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 1:00 p.m. EDT.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of multiple diseases.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.
  • Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

Retrieved on: 
Monday, May 24, 2021

The results suggest that eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) may be an underrecognized cause of chronic unexplained GI symptoms in these patients, and that EG/EoD is highly underdiagnosed.

Key Points: 
  • The results suggest that eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) may be an underrecognized cause of chronic unexplained GI symptoms in these patients, and that EG/EoD is highly underdiagnosed.
  • These data suggest that EG/EoD may be associated with these unexplained chronic GI symptoms in these patients and that targeted EG/EoD therapies could provide a benefit.
  • In practice, gastroenterologists may not always take enough biopsies during upper endoscopy (EGD), especially in the absence of obvious mucosal abnormalities.
  • Published literature reports the prevalence of eosinophilic gastritis and/or eosinophilic duodenitis inthe United Statesto be approximately 50,000 people.